• What does KeyIn-1 do?
  KeyIn-1 is an AI-driven platform that analyzes two inflammation biomarkers, LCN2 and the LCN2–MMP9 complex, to generate an objective molecular profile of a patient’s chronic inflammatory state. By combining biomarker signals with advanced analytics, KeyIn-1 estimates the presence and intensity of inflammation, the level of tissue repair activity, and the balance between ongoing damage and repair.

The output is a set of clear indices and pattern-based groupings that transform complex biology into actionable insight, supporting earlier recognition of disease, more refined assessment of disease activity, and tracking of disease course and treatment efficacy over time. Built on robust biomarkers and a scalable analytic platform, KeyIn-1 is designed for integration into routine care today and extension to other inflammation-driven conditions in the future.

• What makes KeyIn-1 different?
  The applications of KeyIn-1 extend beyond a single disease diagnosis. KeyIn-1 can assist in the differential diagnosis of early disease, quantify inflammation and repair activity in every patient with chronic inflammatory diseases. KeyIn-1 can help evaluate treatment efficacy—capabilities that were previously not accessible through conventional laboratory diagnostics.

• How can KeyIn-1 impact patient care?
  Wide adoption of the KeyIn-1 for Axial Spondyloarthritis and Chronic Low Back Pain populations initially, followed by adoption for other chronic inflammatory diseases, will reduce delays to diagnosis and will provide better assessment of each patient's disease activity. KeyIn-1, once fully deployed, could save at least 10% on current treatment costs for chronic inflammatory diseases.